MarketScreener puts a USD 159.76 target on Merck & Co. stock

Published on 10/26/2026 at 17:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 16.61 billion, up 1.97 percent. Merck & Co. stock costs EUR 126.29 on October 26, 2026, down 2.27 percent versus Xetra close.

Analyst target and reporting date

MarketScreener listed a 27-analyst average target of USD 159.76 on October 23, 2026.
Merck reported USD 16.61 billion in second-quarter 2026 revenue, 1.97 percent above first-quarter revenue.
Merck & Co. stock costs EUR 126.29 at Lang & Schwarz on October 26, 2026 at 5:39 p.m. CET, 2.27 percent below the Xetra close of October 23, 2026.
Merck's ESMO investor event was scheduled for October 26, 2026.

Merck & Co., US58933Y1055, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) was assigned a 27-analyst average target of USD 159.76 in the October 23, 2026 consensus listed by MarketScreener. That target stood 13.13 percent above Merck's USD 141.22 NYSE price at 12:39 p.m. ET on October 26, 2026. At Lang & Schwarz, the stock was trading at EUR 126.29 on October 26, 2026 at 5:39 p.m. CET, down 2.27 percent versus the Xetra close of October 23, 2026 at EUR 129.22.

Revenue provides the second anchor

Merck reported USD 16.61 billion in worldwide sales for the second quarter of 2026, according to its investor-relations page. That was 1.97 percent above the USD 16.29 billion recorded in the first quarter of 2026. The company reported a second-quarter net loss attributable to common shareholders of USD 1.34 billion and diluted earnings per share of minus USD 0.54.

Stock sits below its yearly high

The EUR 126.29 Lang & Schwarz price was 7.44 percent below the EUR 136.44 52-week high and above the EUR 71.30 52-week low on the same euro quotation. The NYSE stock traded at USD 141.22 at 12:39 p.m. ET, while volume reached 4,425,039 shares. The separate currency quotations should not be combined into one daily move.

Valuation and the next date

Merck's NYSE market capitalization was USD 348.4 billion on October 26, 2026, with a P/E ratio of 113.02 and a dividend yield of 2.00 percent. Its investor-relations page listed an investor event at ESMO for October 26, 2026 and identified the company as NYSE-listed under the ticker MRK.

Comparison with peers

Merck & Co.: down 2.79 percent, P/E 113.02, market capitalization USD 348.4 billion. Bristol-Myers Squibb Company (NYSE, USD): down 0.42 percent, P/E 13.49, market capitalization USD 125.1 billion. Johnson & Johnson (NYSE, USD): up 0.54 percent, P/E 40.21, market capitalization USD 638.5 billion.

What the target says

The USD 159.76 consensus target gives the analyst view a measurable distance from Merck's USD 141.22 NYSE quotation. The stock's euro quotation, however, remained below the October 23 Xetra close at the latest Lang & Schwarz timestamp.

Price and dates for investors

Merck & Co. stock was trading at EUR 126.29 at Lang & Schwarz on October 26, 2026 at 5:39 p.m. CET, down 2.27 percent versus the Xetra close of October 23, 2026 at EUR 129.22. The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.